Granted Patent
B2
US 12,472,251 · App. 17/239,983 · Granted Nov 18, 2025
Method for treating fibrosis with an anti-GDF-15 antibody
Assignee:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
A61K39/3955A61P11/00A61K38/1841A61K2039/505C07K14/475C07K14/495C07K16/22C07K2317/76C07K2319/30C07K2319/32C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.
Claims (7)
1 . A method of treating fibrosis in a subject in need of treatment thereof, the method comprising administering an inhibitor of growth differentiation factor 15 (GDF-15) to the subject, wherein the inhibitor is an antibody that binds GDF-15, and wherein the subject is a subject having or diagnosed as having a disease or condition selected from the group consisting of: interstitial vascular disease, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and emphysema.
2 . The method of claim 1 , wherein the inhibitor is specific for GDF-15.
3 . The method of claim 1 , wherein the subject is determined to have an increased level of GDF-15 relative to a control.
4 . The method of claim 1 , wherein the subject is a subject having or diagnosed as having interstitial vascular disease.
5 . The method of claim 1 , wherein the subject is a subject having or diagnosed as having idiopathic pulmonary fibrosis.
6 . The method of claim 1 , wherein the subject is a subject having or diagnosed as having chronic obstructive pulmonary disease (COPD).
7 . The method of claim 1 , wherein the subject is a subject having or diagnosed as having emphysema.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 23, 2021
From: YUNG, LAI-MING; YU, PAUL B.
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 057252/0728 →
Continuity (4)
Continuation
15327741
Provisional Application
62031924
· Aug 1, 2014
References Cited (95)
US 6294350B1
· Peterson
· 2001
[cited by applicant]
US 7157235B2
· Breit
· 2007
[cited by examiner]
US 7919084B2
· Breit
· 2011
[cited by examiner]
US 9809637B2
· Kumar et al.
· 2017
[cited by applicant]
US 20050203022A1
· Gotwals et al.
· 2005
[cited by applicant]
US 20080009500A1
· Kahn
· 2008
[cited by applicant]
US 20100003256A1
· Sheppard et al.
· 2010
[cited by applicant]
US 20100248288A1
· Hess et al.
· 2010
[cited by applicant]
US 20110172296A1
· Bennett et al.
· 2011
[cited by applicant]
US 20110319406A1
· Kim et al.
· 2011
[cited by applicant]
US 20130287688A1
· Jain et al.
· 2013
[cited by applicant]
US 20150056199A1
· Kumar
· 2015
[cited by examiner]
US 20150239968A1
· Wischhusen et al.
· 2015
[cited by applicant]
US 20170137505A1
· Gyuris et al.
· 2017
[cited by applicant]
CN 101020928A
· 2007
[cited by applicant]
CN 101262877A
· 2008
[cited by applicant]
CN 103732623B
· 2014
[cited by applicant]
EP 0975771B1
· 2007
[cited by applicant]
EP 2372364A1
· 2011
[cited by applicant]
EP 2597466A1
· 2013
[cited by applicant]
KR 20100013851A
· 2010
[cited by applicant]
KR 101346132B1
· 2013
[cited by applicant]
KR 101346181B1
· 2014
[cited by applicant]
WO 1998048024A1
· 1998
[cited by applicant]
WO 1999065948A1
· 1999
[cited by applicant]
WO 2005010049A2
· 2005
[cited by applicant]
WO 2009026204A1
· 2009
[cited by applicant]
WO 2012093125A1
· 2012
[cited by applicant]
WO 2012145539A1
· 2012
[cited by applicant]
WO 2013019805A1
· 2013
[cited by applicant]
WO 2013023557A1
· 2013
[cited by applicant]
WO 2013059879A1
· 2013
[cited by applicant]
WO 2014049087A1
· 2014
[cited by applicant]
WO 2014111458A2
· 2014
[cited by applicant]
WO 2015027082A1
· 2015
[cited by applicant]
WO 2015179227A1
· 2015
[cited by applicant]
WO 2015189790A1
· 2015
[cited by applicant]
Pitsiou et al (2011. Respiration. 82: 294-304).
[cited by examiner]
Yanaba et al (2012. Mod Rheumatology. 22: 668-675).
[cited by examiner]
Baybutt et al. “Effects on cytokines and histology by treatment with the ACE inhibitor captopril and the antioxidant retinoic acid in the monocrotaline model of experimentally induced lung fibrosis.” Current pharmaceuti…
[cited by applicant]
Hayashi et al. “Establishment of an animal model for pulmonary fibrosis in mice using monocrotaline.” Toxicologic pathology 23(1): 63-71 (1995).
[cited by applicant]
Heupel et al. “Loss of transforming growth factor-beta 2 leads to impairment of central synapse function.” Neural development 3(1): 1-16 (2008).
[cited by applicant]
Nickel et al. “GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells.” Respiratory research 12.1: 62 …
[cited by applicant]
Sun et al., “Growth Differentiation Factor-15 and Cardiovascular Disease.” Chinese Journal of Arteriosclerosis 18(2) (2010).
[cited by applicant]
Fox et al., “Pulmonary arterial hypertension: classification, diagnosis and contemporary management.” Postgraduate medical journal 82.973 (2006): 717-722.
[cited by applicant]
Tokuriki et al., “Stability effects of mutations and protein evolvability.” Current opinion in structural biology 19.5 (2009): 596-604.
[cited by applicant]
Park et al. “Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy”. Pharmacol Res. 43(3):265-73 (2001).
[cited by applicant]
Akhurst et al., “Targeting the TGFβ signalling pathway in disease”, Nature Reviews Drug Discovery 11(10):790-811 (2012).
[cited by applicant]
Anderton et al., “Induction of heart valve lesions by small-molecule ALK5 inhibitors.” Toxicologic Pathology 39 (6):916-924 (2011).
[cited by applicant]
Botney et al., “Vascular Remodeling in Primary Pulmonary Hypertension: Potential Role for Transforming Growth Factor-β”, American Journal of Pathology 144(2):285-295 (1994).
[cited by applicant]
Cao et al., “Changes of calponin and TGFbeta1 in pulmonary artery smooth muscle of pulmonary artery hypertension rats.” Chinese Pharmacological Bulletin 23(2):277-278 (2007).
[cited by applicant]
Chen et al., “Dominant negative mutation of the TGF-β receptor blocks hypoxia-induced pulmonary vascular remodeling”, Journal of Applied Physiology 100:564-571 (2006).
[cited by applicant]
Czajkowsky et al., “Fc-fusion proteins: new developments and future perspectives”, EMBO Molecular Medicine 4 (10):1015-1028 (2012).
[cited by applicant]
Derrett-Smith et al., “Endothelial Injury in a Transforming Growth Factor β-Dependent Mouse Model of Scleroderma Induces Pulmonary Arterial Hypertension”, Arthritis & Rheumatism 65(11):2928-2939 (2013).
[cited by applicant]
Gong et al., “Hypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling”, American Journal of Physiology-Lung Cellular and Mol…
[cited by applicant]
Gonzaelez-Nunez et al., “The ALK-1/SMAD1 pathway in cardiovascular physipathology: a new target for therapy?”, Biochem Biophys Acta 1832(10):1492-1510 (2013).
[cited by applicant]
Gordon et al., “Role of transforming growth factor-beta superfamily signaling pathways in human disease”, Biochimica et Biophysica Acta, 1782(4): 197-228 (2008).
[cited by applicant]
Grafe et al., “Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta.” Nature Medicine 20(6):670-675 (2014).
[cited by applicant]
Graham et al., “Transforming Growth Factor-β Signaling Promotes Pulmonary Hypertension Caused by Schistosoma Mansoni”, Circulation 128:1354-1364 (2013).
[cited by applicant]
Harrison et al., “Transforming Growth Factor-β Receptor Mutations and Pulmonary Arterial Hypertension in Childhood”, Circulation 111:435-441 (2005).
[cited by applicant]
Hatton et al., “Transforming growth factor signalling: a common pathway in pulmonary arterial hypertension and systemic sclerosis.” International Journal of Clinical Practice 65:35-43 (2011).
[cited by applicant]
Huang et al. “Diet-induced macrophage inhibitory cytokine 1 promotes prostate cancer progression.” Endocrine-Related Cancer 21(1): 39-50 (2014).
[cited by applicant]
Li et al. “Purification and Characterization of the Fusion Protein TGF-betaR II/Fc.” Chin. J. Cell. Mol. Immunol. 19(4): 400-402 (2003) [English Abstract].
[cited by applicant]
Long et al., “Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression …
[cited by applicant]
Meadows et al., “Increased expressin of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypetension”, Chest 139(5):994-1002 (2010).
[cited by applicant]
Megalou et al., “Transforming growth factor-β inhibition and endothelin receptor blockade in rats with monocrotaline-induced pulmonary hypertension”, Pulmonary Circulation 2(4):461-469 (2012).
[cited by applicant]
Megalou et al., “Transforming growth factor-β inhibition attenuates pulmonary arterial hyerptension in rats”, International Journal of Clinical and Experimental Medicine 3(4): 332-340 (2010).
[cited by applicant]
Montani et al., “Targeted therapies in pulmonary arterial hypertension”, Pharmacology & Therapeutics 141:172-191 (2014).
[cited by applicant]
Nasim et al., “BMPR-II deficiency elicits pro-proliferative and anti-apoptotic response through the activation of TGFβ-TAK1-MAPK pathways in PAH”, Human Molecular Genetics 21(11):2548-2558 (2012).
[cited by applicant]
Ogo et al., “Inhibition of Overactive Transforming Growth Factor-β Signaling by Prostacyclin Analogs in Pulmonary Arterial Hypertension”, Am J Respir Cell Mol Biol. 48(6):733-741 (2013).
[cited by applicant]
Perkett et al., “Transforming Growth Factor-β Activity in Sheep Lung Lymph during the Development of Pulmonary Hypertension”, Journal of Clinical Investigation 86:1459-1464 (1990).
[cited by applicant]
Rabbani et al., “Soluble TGFβ Type II Receptor Gene Therapy Ameliorates Acute Radiation-Induced Pulmonary Injury in Rats”, International Journal of Radiation Oncology* Biology* Physics 57 (2):563-572 (2003).
[cited by applicant]
Rainer et al., “Cardiomyocyte-Specific Transforming Growth Factor β Suppression Blocks Neutrophil Infiltration, Augments Multiple Cytoprotective Cascades, and Reduces Early Mortality After Myocardial Infarction”, Circul…
[cited by applicant]
Samuel et al., “Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease”, Hypertension 64(2):315-322 (2014).
[cited by applicant]
Thomas et al., “Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental…
[cited by applicant]
Upton et al., “The transforming growth factor-β-bone morphogenetic protein type signaling pathway in pulmonary vascular homeostasis and disease”, Experimental Physiology 98(8):1262-1266 (2013).
[cited by applicant]
Upton et al., “Transforming Growth Factor-β1 Represses Bone Morphogenetic Protein-Mediated Smad Signaling in Pulmonary Artery Smooth Muscle Cells via Smad3”, American Journal of Respiratory Cell and Molecular Biology 49…
[cited by applicant]
Wang et al. “Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.” Cancer Science 105(2): 176-185 (2014).
[cited by applicant]
Yung et al., “A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension”, American Journal of Respiratory and Critical Care Medicine 194(9):1140-1151 (2016).
[cited by applicant]
Zaiman et al., “Role of the TGF-β/ALK5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension”, American Journal of Respiratory and Critical Care Medicine 177:896-905 (2008).
[cited by applicant]
Record for GenBank M85079; available at https://www.ncbi.nlm.nih.gov/nuccore/M85079; 2 pages as printed, no author indicated (1995).
[cited by applicant]
Yue et al., “TGF-β: titan of lung fibrogenesis.” Current enzyme inhibition 6.2: 67-77 (2010).
[cited by applicant]
Huang et al., “Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis.” American journal of respiratory cell and molecular biology 46.1: 87-95 (2012).
[cited by applicant]
Lambrecht et al. “Growth differentiation factor 15, a marker of lung disease in systemic sclerosis, is involved in fibrosis development but does not impair fibrosis development.” The American College of Rheumatology (AC…
[cited by applicant]